E
Eccogene
Innovative drug discovery for metabolic and immune-related diseases with a focus on translational medicine
About Eccogene
Eccogene is a biotechnology company dedicated to the discovery and development of innovative therapies for metabolic and immune-related diseases. The company operates in the biopharmaceutical sector, targeting conditions such as cardiometabolic diseases and non-alcoholic fatty liver disease (NAFLD). Eccogene's business model revolves around translational medicine, which aims to translate scientific research into effective clinical treatments. The company generates revenue through licensing agreements and partnerships with major pharmaceutical companies. For instance, Eccogene recently entered an exclusive license agreement with AstraZeneca to develop and commercialize a small molecule GLP-1 receptor agonist, ECC5004, for cardiometabolic diseases, securing an initial upfront payment of $185 million. Eccogene serves a global market, focusing on unmet medical needs and leveraging its scientific expertise to bring differentiated therapies to patients. The company has also raised significant financing, including over 100 million RMB in a recent funding round led by Oriza Seed and Delos Capital, with participation from new and existing investors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Huangpu, China
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 84.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2023 | $25M | $99M | Delos Capital · Oriza Seed Capital · New Alliance Capital · Qingsong Capital | ↗ |
| SERIES AEquity / VC | Sep 2018 | $15M | $59M | Sinopharm Capital · TF Capital · Med-Fine Capital | — |
Growth signals
Latest recorded traffic for Eccogene is 950 monthly website visits, down 50% over the last three months. Eccogene's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
- SCSinopharm Capital
TF Capital
Med-Fine Capital
New Alliance Capital- ZCZhangjiang Healthcare Venture Capital
Delos Capital- OCOriza Seed Capital
- QCQingsong Capital
- EVElikon Venture
- RCRockbleu Capital
- YIYuFu Investment
Huajin Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eccogene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eccogene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.